Co-transplantation of MSC in the Setting of Allo-HSCT

Launched by FUJIAN MEDICAL UNIVERSITY · Jan 29, 2020

Keywords

ClinConnect Summary

This clinical trial is studying the use of mesenchymal stem cells (MSCs) in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). MSCs are special cells that can help reduce inflammation and improve healing, which may lead to better outcomes after a transplant. The researchers want to see if infusing MSCs during the transplant process can help patients recover more effectively, reduce the chances of complications like graft versus host disease (GVHD), and improve overall survival.

To participate in this trial, you need to be under 65 years old, in good health with a functioning heart, liver, and kidneys, and able to give consent. This means you should be willing to undergo the transplant and have a good level of physical ability. If you are pregnant or have certain health issues that would make it unsafe for you to receive MSCs, you won’t be eligible. Participants will receive MSCs during their transplant and will be monitored closely for their recovery and any side effects. This trial is currently recruiting, so if you think you might be a candidate, it could be a great opportunity to contribute to important research while potentially benefiting from this new approach.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Signed written informed consent
• • Aged \<65 years
• • Willing to transplant
• • Cardiac: Left ventricular ejection fraction ≥ 50%
• • Adequate renal and hepatic function
• • Performance status: Karnofsky ≥ 70%
• Exclusion Criteria:
• • Pregnant or lactating females.
• • Any co-morbidity precluding the administration of MSCs.